Chemoradiation with or without immunotherapy for anal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an immunotherapy drug (retifanlimab) to standard chemoradiation improves outcomes for people with locally advanced anal cancer. The treatment is adjusted based on HPV DNA levels in your blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have anal cancer that has not spread to distant organs and is at a certain stage (T1-4N+ or T3-4N0).
- You are 18 years or older.
- You are in generally good health (able to care for yourself, ECOG 0-2).
- Your kidney function is adequate (creatinine clearance above 30 ml/min).
- You have not had chemotherapy for anal cancer before, and no prior radiation to the pelvic area.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug pembrolizumab, two chemotherapy drugs (carboplatin and paclitaxel), and radiation for people with early-stage anal cancer who cannot take the usual chemotherapy. The goal is to see if this approach is safe and effective as an alternative treatment.
This trial tests a shorter course of radiation therapy given with chemotherapy for people with high-risk anal cancer. The goal is to see if the shorter treatment is just as effective but causes fewer side effects and is more convenient.
This trial checks whether tumor samples contain HPV DNA (genetic material from the HPV virus). The goal is to improve detection in anal and cervical cancers, especially in patients planning standard radiation treatment.
This trial uses a blood test to track tumor DNA in patients with HPV-related cervical or anal cancer. It aims to see if this test can detect early signs of recurrence after radiation therapy, helping guide follow-up care.
This trial tests if giving chemotherapy before standard chemoradiation works better than standard chemoradiation alone for people with locally advanced anal cancer that has not spread. It aims to improve treatment outcomes.
This study tests a combination of chemotherapy, radiation therapy, and an immunotherapy drug (anti-PD-1 antibody) for anal squamous cell cancer. The trial enrolls patients at different stages of disease to see if adding immunotherapy improves outcomes.
Hear when a new Anal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.